“Trump taps biotech investor Jim O’Neill for HHS deputy secretary”
President Donald Trump’s nomination of Jim O’Neill for the role of Deputy Secretary at the Department of Health and Human Services (HHS) has brought to light O’Neill’s extensive affiliations with the biotechnology sector, prompting discussions about potential conflicts of interest and the need for stringent ethical safeguards.
Professional Background and Industry Involvement
Jim O’Neill is a seasoned figure in both public service and the biotech investment landscape. He previously served as Principal Associate Deputy Secretary at HHS during the George W. Bush administration, where he oversaw policy and regulatory matters for agencies such as the NIH, FDA, and CDC. Beyond his government tenure, O’Neill has been deeply involved in the biotech industry, notably through his roles with ADvantage Therapeutics and Rational Vaccines.
At ADvantage Therapeutics, a company developing therapies for neurodegenerative conditions like Alzheimer’s disease, O’Neill has served as both an advisor and a member of the board of directors. His financial disclosures indicate that he received over $60,000 from the company and holds vested and unvested stock options valued between $1,001 and $50,000. Additionally, he is eligible for discretionary bonuses based on his performance in 2023 and 2024, which he has committed to forfeiting upon confirmation to the HHS role.
O’Neill also holds a position as Global Health Advisor at Rational Vaccines, a firm focused on developing vaccines for herpes simplex virus infections. His disclosures reveal anticipated consulting fees ranging from $15,001 to $50,000, which he has agreed to forgo if confirmed.
Ethical Concerns and Legislative Scrutiny
The nomination has elicited concerns from lawmakers regarding potential conflicts of interest. Senator Elizabeth Warren has called for O’Neill to commit to a four-year recusal from any decisions involving his former clients and employers, as well as a pledge not to seek employment or compensation from companies he regulated during his tenure for the same period after leaving office.
While O’Neill has agreed to recuse himself from specific matters related to ADvantage Therapeutics for up to two years, depending on compensation received, he has not publicly committed to the broader four-year recusal period requested by Senator Warren.
Implications for HHS Leadership
If confirmed, O’Neill would serve under HHS Secretary Robert F. Kennedy Jr., who has advocated for reducing industry influence within public health agencies. O’Neill’s extensive ties to the biotech sector and his previous statements advocating for FDA reforms—such as approving drugs based solely on safety without requiring proof of efficacy—could influence policy directions within the department.
Source article posted here: https://www.statnews.com/2025/04/03/jim-oneill-hhs-deputy-secretary-nominee-financial-disclosures/
Follow Naomi Wolf on Substack: https://naomiwolf.substack.com
Follow ‘Outspoken’ on Rumble! https://rumble.com/c/DrNaomiWolfOutspoken
Donate to DailyClout: https://ko-fi.com/dailyclout
Please Support Our Sponsors
The Wellness Company: https://dailyclouthealth.com
Use code DAILYCLOUT for 10% off!
NativePath: “7 Reasons Why Men & Women Over 50 Are Adding This Single Ingredient To Their Morning Routine. Visit https://getnativepath.com/DailyClout to Learn More…”
CrateClub: “Unleash your inner operator with https://DailyCloutGear.com —monthly drops of elite outdoor, survival, and tactical gear built for those who never stand down.”
Order ‘The Pfizer Papers’ and Support Our Historic Work: https://www.amazon.com/dp/1648210376?&tag=skyhorsepub-20
Discover LegiSector! Stay up-to-date on issues you care about with LegiSector’s state-of-the-art summarizing capabilities and customizable portals. No researchers needed, no lobbyists, no spin. Legislation at your fingertips! Learn more at https://www.legisector.com/